Oruka's ORKA-001 achieves complete skin clearance in 61% of high-dose patients in Phase 2b psoriasis trial

PUBT · 1d ago
Oruka's ORKA-001 achieves complete skin clearance in 61% of high-dose patients in Phase 2b psoriasis trial
  • Oruka Therapeutics announced positive Phase 2b EVERLAST-B results for ORKA-001 in moderate-to-severe plaque psoriasis, supporting planned Phase 3 development.
  • The highest dose produced complete skin clearance in most patients, with results consistent with the earlier EVERLAST-A trial.
  • Treatment was well tolerated, with no serious treatment-emergent adverse events in the high-dose group.
  • Phase 3 trials are planned for the first half of 2027, pending regulatory discussions.
  • Longer-term results are expected from EVERLAST-A in December 2026, followed by EVERLAST-B in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260700PRIMZONEFULLFEED9852808) on October 26, 2026, and is solely responsible for the information contained therein.